Iltamiocel

BIOLOGICAL4 trials

Sponsors

Cook MyoSite

Conditions

Fecal IncontinenceStress Urinary Incontinence

Phase 1

Autologous Cell Therapy for Treatment of Fecal Incontinence

CompletedNCT01600755

Cook MyoSiteFecal Incontinence

Start: 2013-03-28End: 2021-10-27Updated: 2024-02-16

Phase 3

Autologous Muscle Derived Cells for Female Urinary Sphincter Repair

CompletedNCT01893138

Cook MyoSiteStress Urinary Incontinence

Start: 2013-11-21End: 2020-11-10Updated: 2023-01-05

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

Active, not recruitingNCT05776277

Cook MyoSiteFecal Incontinence

Start: 2024-03-21End: 2027-12-01Target: 200Updated: 2026-07-21

Unknown Phase

Observational Registry for Iltamiocel Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Enrolling by invitationNCT06743620

Cook MyoSiteStress Urinary Incontinence

Start: 2025-04-11End: 2032-04-01Target: 96Updated: 2026-07-22

Related Papers

Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double‐Blind, Randomized, Stratified, Placebo‐Controlled Trial

Neurourology and Urodynamics2024-09-162 citations

PD06-01 A DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL COMPARING SAFETY AND EFFICACY OF AUTOLOGOUS MUSCLE DERIVED CELLS FOR URINARY SPHINCTER REPAIR (AMDC-USR) WITH PLACEBO (PBO) IN WOMEN WITH STRESS URINARY INCONTINENCE (SUI)

The Journal of Urology2021-08-041 citations

PD06-02 AN EVALUATION OF WOMEN WITH PERSISTENT OR RECURRENT STRESS URINARY INCONTINENCE (SUI) FOLLOWING SURGERY IN A DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL COMPARING SAFETY AND EFFICACY OF AUTOLOGOUS MUSCLE DERIVED CELLS FOR URINARY SPHINCTER REPAIR (AMDC-USR) WITH PLACEBO (PBO)

The Journal of Urology2021-08-04